key: cord-0988361-s33p3s21
authors: Taxonera, Carlos; Sagastagoitia, Iñigo; Alba, Cristina; Mañas, Norberto; Olivares, David; Rey, Enrique
title: Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2—exploring RAS inhibitors. Authors’ reply
date: 2020-06-25
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15893
sha: da1c0ec5250586fd6783bc7a6d5d1d56a392805e
doc_id: 988361
cord_uid: s33p3s21

LINKED CONTENT This article is linked to Taxonera et al an Garg et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15814.

by the high affinity of the SARS-CoV-2 spike (S) protein for the angiotensin-converting enzyme 2 (ACE2), which is overexpressed in the inflamed gastrointestinal (GI) tract of IBD patients and considered to be essential for viral entry into human cells.

Garg et al exhaustively analysed the potential influence of all major components of the renin-angiotensin system (RAS), including ACE2, on GI symptoms in patients with COVID-19. 1 The authors postulated that intestinal inflammation leading to symptoms may occur due to SARS-CoV-2-mediated reduction of mucosal ACE2 following entry, resulting in elevated angiotensin II, reduced angiotensin 1-7, increased tumour necrosis factor (TNF) and tryptophan deficiency. 3 Since reduced ACE2 expression in the lungs has also been associated with acute respiratory distress syndrome, it has been suggested that drugs targeting RAS may be useful for the treatment of COVID-19. 4 However, in view of additional data showing no effect of ACE inhibitors and angiotensin receptor blockers on ACE2 GI expression, it is unlikely that these drugs could influence SARS-CoV-2 infection of the GI tract. 2 The reported evidence, however, suggests other potential therapeutic targets for COVID-19. In severely ill COVID-19 patients, biologics may be beneficial through control of the cytokine release storm, which bears some resemblance to the process in IBD flares. IL-6 levels are significantly elevated in COVID-19, and treatment with the anti-IL-6 antibody tocilizumab dramatically decreases CRP levels, suggesting an improvement in this hyper-inflammatory state. 5 Interestingly, a recent study of patients included in the SECURE-IBD registry reported that TNF antagonist monotherapy was not associated with and even may have a protective effect against severe COVID-19. 6 Evidence that mucosal or plasma ACE2 expression or activity was not associated with the use of anti-TNF therapies 3 reinforces the need for trials evaluating these drugs for COVID-19. 7 We agree with the authors' comment about interest in the relationship between GI symptoms and faecal calprotectin (FC). FC levels seem especially useful in symptomatic IBD patients to confirm an active flare, but elevated FC also occurs in acute bacterial and viral gastroenteritis. 8 For example, a study reported high FC levels in COVID-19 non-IBD patients with resolved or ongoing diarrhoea. 9 Therefore, we believe that FC levels in a COVID-19 IBD patient with diarrhoea may not be helpful in discriminating between an IBD flare and diarrhoea associated with intestinal cell colonisation by SARS-CoV-2. As no relationship was observed between FC and faecal ARS-CoV-2-RNA, FC levels did not seem useful in evaluating the elimination of virus from the faeces. However, FC levels <100 μg/g in patients with GI symptoms could be useful in differentiating between organic and non-organic gastrointestinal disease, thus avoiding the need for unnecessary endoscopic evaluation during pandemic.

The authors thank Dr. G. Morley for reviewing the English manuscript.

The authors' declarations of personal and financial interests are unchanged from those in the original article. 1 P < 0.001), in line with previous findings. 3 We also did not find a correlation between the degree of transaminitis and hypoxaemia on admission defined by a blood oxygen saturation level < 94% (r = 0.06, P = 0.42) suggesting no direct link between COVID-19-induced initial hypoxemia and liver damage.

In addition, we have explored the impact of pre-existing liver diseaseincluding cirrhosis, on the outcomes of COVID-19, which we feel is of great importance. Immune dysfunction has been well described in cirrhotic patients resulting in a high risk of infection and cirrhotic patients have poor outcomes with acute respiratory distress syndrome (ARDS). 4 To summarise, our findings suggest that: i. one third of COVID-19 patients have mild transaminitis, which may be associated with more severe disease but not increased mortality; ii. liver cirrhosis does not predispose to increase mortality but does increase length of stay.

Further outcome data from large registries of COVID-19 patients with cirrhosis are awaited to confirm this.

Declaration of personal interests: None. 

Novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

Letter: gastrointestinal ACE2, COVID-19 and IBD-opportunity in the face of tragedy?

Counter-regulatory 'Renin-Angiotensin' system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients

Clinical outcomes in COVID-19 patients treated with tocilizumab: an individual patient data systematic review

Corticosteroids but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

The utility of fecal calprotectin in the era of COVID-19 pandemic

Faecal calprotectin indicates intestinal inflammation in COVID-19